Validation of dosage forms MCQs With Answer

Validation of Dosage Forms MCQs With Answer provides a focused, exam-oriented practice set for M. Pharm students studying Modern Pharmaceutics (MPH 103T). This quiz emphasizes the lifecycle approach to process validation, linking concepts from ICH Q8/Q9/Q10/Q12, FDA’s 2011 Process Validation Guidance, EU Annex 15, and sterile product expectations (Annex 1). You’ll tackle PPQ strategy, equipment qualification, blend uniformity, CPV, and risk management, as well as sterile validation essentials like filtration, media fills, and depyrogenation. Analytical and cleaning validation, MACO via health-based limits, and CCIT also feature prominently. Each question tests application-level understanding, mirroring real-world regulatory expectations and industrial best practices to help you master validation of dosage forms.

Q1. Which statement best defines process validation in pharmaceutics?

• A documented program providing high degree of assurance that a specific process consistently produces a product meeting its predetermined specifications and quality attributes
• An activity aimed at proving the batch record is correctly signed
• The final QC test that releases the batch
• A regulatory activity performed only during inspections

Correct Answer: A documented program providing high degree of assurance that a specific process consistently produces a product meeting its predetermined specifications and quality attributes

Q2. According to the modern lifecycle approach, which are the three stages of process validation?

• Process Design, Process Qualification (including PPQ), and Continued Process Verification
• Design Qualification, Installation Qualification, and Operational Qualification
• Qualification, Validation, and Verification
• Process Mapping, Design of Experiments, and Quality by Design

Correct Answer: Process Design, Process Qualification (including PPQ), and Continued Process Verification

Q3. What is the correct sequence for equipment/system qualification?

• URS → DQ → IQ → OQ → PQ
• IQ → OQ → PQ → DQ
• DQ → PQ → OQ → IQ
• URS → IQ → DQ → OQ → PQ

Correct Answer: URS → DQ → IQ → OQ → PQ

Q4. How should the number of PPQ batches be determined for a new commercial process?

• Statistically justified number based on process knowledge and risk (commonly three or more consecutive commercial-scale batches)
• Always exactly three batches by law
• One batch if in-process tests pass
• Five pilot batches irrespective of scale

Correct Answer: Statistically justified number based on process knowledge and risk (commonly three or more consecutive commercial-scale batches)

Q5. What is the primary intent of blend uniformity evaluation during process validation of tablets/capsules?

• Homogeneous distribution of API in the bulk blend to support uniformity of dosage units
• Adequate granule size distribution for flow
• Lubrication time adequacy
• Residual solvent levels below ICH Q3C limits

Correct Answer: Homogeneous distribution of API in the bulk blend to support uniformity of dosage units

Q6. Which principle best reflects current best practice for setting cleaning validation limits (MACO)?

• Health-based exposure limits (e.g., PDE/ADI) used to calculate MACO considering next product and batch size
• 10 ppm of previous product in next product is universally acceptable without justification
• Visual cleanliness alone is sufficient
• Using always 1/1000th of minimum daily dose regardless of potency

Correct Answer: Health-based exposure limits (e.g., PDE/ADI) used to calculate MACO considering next product and batch size

Q7. Why are swab recovery studies critical in cleaning validation?

• Determines the fraction of residue recovered from the surface to correct analytical results
• Measures equipment surface roughness
• Replaces analytical method validation
• Eliminates the need for rinse sampling

Correct Answer: Determines the fraction of residue recovered from the surface to correct analytical results

Q8. What must hold-time validation for intermediates (e.g., granules, bulk solutions) demonstrate?

• Demonstrate that intermediates maintain quality within predefined storage conditions and time, without adverse impact on CQAs
• Reduce overall manufacturing time
• Establish shelf-life of finished product
• Replace long-term stability studies

Correct Answer: Demonstrate that intermediates maintain quality within predefined storage conditions and time, without adverse impact on CQAs

Q9. Which organism is used to validate bacterial retention of 0.22 μm sterilizing-grade membrane filters?

• Brevundimonas diminuta (ATCC 19146)
• Staphylococcus aureus
• Bacillus subtilis spores
• Escherichia coli

Correct Answer: Brevundimonas diminuta (ATCC 19146)

Q10. Which integrity tests are typically applied to sterilizing-grade filters?

• Bubble point, diffusion/forward flow, and pressure-hold tests
• HPLC assay
• HEPA filter DOP challenge test
• Endotoxin gel-clot test

Correct Answer: Bubble point, diffusion/forward flow, and pressure-hold tests

Q11. In moist-heat sterilization, how is F0 correctly defined?

• Equivalent exposure time at 121.1°C based on a z-value of 10°C delivering the same lethality
• The time to reach 121.1°C from ambient temperature
• The log reduction of endotoxin during dry heat sterilization
• The overkill approach of 12 log reduction of spores at 250°C

Correct Answer: Equivalent exposure time at 121.1°C based on a z-value of 10°C delivering the same lethality

Q12. What is the typical acceptance criterion for aseptic process simulations (media fills)?

• Zero contaminated units; any growth invalidates the run unless properly investigated and justified
• Up to 1% contaminated units is acceptable
• Contamination is acceptable if below an alert limit
• Only positive controls should show growth

Correct Answer: Zero contaminated units; any growth invalidates the run unless properly investigated and justified

Q13. Which container closure integrity test (CCIT) method is deterministic?

• Helium mass spectrometry leak detection
• Dye ingress with methylene blue
• Microbial ingress immersion test
• Bubble immersion (blue dye) test

Correct Answer: Helium mass spectrometry leak detection

Q14. In endotoxin testing (LAL), how is the Maximum Valid Dilution (MVD) calculated?

• MVD = (Endotoxin limit × sample concentration) / λ
• MVD = λ × Endotoxin limit × sample concentration
• MVD = Endotoxin limit / λ
• MVD = (λ × sample concentration) / Endotoxin limit

Correct Answer: MVD = (Endotoxin limit × sample concentration) / λ

Q15. Which set lists the analytical method validation characteristics defined in ICH Q2(R2)?

• Accuracy, precision (repeatability and intermediate precision), specificity, linearity, range, detection limit, quantitation limit, robustness
• Only accuracy and precision
• System suitability and ruggedness only
• Recovery and selectivity only

Correct Answer: Accuracy, precision (repeatability and intermediate precision), specificity, linearity, range, detection limit, quantitation limit, robustness

Q16. What does the process capability index Cpk quantify?

• The minimum of the distance from the process mean to the nearest specification limit divided by three standard deviations
• The ratio of tolerance to six times standard deviation without considering centering
• The percent of defects per million opportunities
• An index used only for equipment qualification

Correct Answer: The minimum of the distance from the process mean to the nearest specification limit divided by three standard deviations

Q17. What is the primary focus of Continued Process Verification (CPV) in the validation lifecycle?

• Ongoing assurance during commercial production using statistical process control, trending of CPPs/CQAs, and periodic review
• Final batch release testing only
• Activities performed only during the validation stage
• Retrospective review after product discontinuation

Correct Answer: Ongoing assurance during commercial production using statistical process control, trending of CPPs/CQAs, and periodic review

Q18. Which is a recognized quality risk management tool under ICH Q9?

• Failure Mode and Effects Analysis (FMEA)
• Atomic absorption spectroscopy
• Karl Fischer titration
• Gas chromatography

Correct Answer: Failure Mode and Effects Analysis (FMEA)

Q19. Which statement about design space under ICH Q8(R2) is correct?

• Movement within an approved design space is not considered a change; movement outside is a change requiring regulatory action
• Any movement within design space requires prior approval
• Design space is identical to the proven acceptable range of a single in-process parameter
• Design space can be changed unilaterally after approval without notification

Correct Answer: Movement within an approved design space is not considered a change; movement outside is a change requiring regulatory action

Q20. What is the standard performance requirement for depyrogenation tunnel validation for glass containers?

• Demonstrate at least 3-log10 endotoxin reduction (using an endotoxin challenge) on items such as vials
• Demonstrate 6-log10 spore reduction with moist heat
• Achieve 0.22 μm filtration of environmental air
• Maintain relative humidity below 50% in the tunnel

Correct Answer: Demonstrate at least 3-log10 endotoxin reduction (using an endotoxin challenge) on items such as vials

Download